- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04197726
Glycaemic Response to High REsistant STarch Bread (REST)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In an attempt to increase dietary fibre intake, research has focused on developing wheat-based food products with novel fibres and starches to complement fibre intake from whole grain foods. Resistant starch is starch that escapes digestion in the small intestine and may be fermented in the large intestine by the microbiota. Resistant starch is a type of dietary fibre and it is normally found in wheat-based foods made from refined flour but only in small amounts. White bread made from sbeIIa/b wheat, which has high levels of resistant starch (a type of fibre), is showing promise in modulating blood glucose response and increasing satiety compared with conventional white bread.
The primary aim of this study is to determine whether consumption of sbeIIa/b white bread at breakfast, gives rise to a lower postprandial blood glucose response compared with consumption of a reference white bread in healthy individuals.
Additional aims of the study include: determining whether consumption of sbeIIa/b white bread by healthy subjects, gives rise to a lower glucose concentration in interstitial fluid, as measured by a Continuous Glucose Monitoring system (CGM), compared with consumption of control white bread; and exploring satiety and energy intake changes in healthy individuals following consumption of sbeIIa/b white bread at breakfast, compared with consumption of control white bread.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Norfolk
-
Norwich, Norfolk, United Kingdom, NR4 7UQ
- Quadram Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women
- Aged 18 to 65 years
- BMI between 18-25 kg/m2
- Non-smokers
- Those that live within a 40-mile radius of Norwich
Exclusion Criteria:
- Fasting glucose >6.1 mmol/L and/or HbA1c>42 mmol/mol, as assessed by a fasting blood test
- Eligibility screening results indicate they are not suitable to take part in this study
- Smokers (if they have smoked within the 6 weeks prior to the study or during the study)
- Suffer from allergy, intolerance, or sensitivity to gluten, yeast or any of the food ingredients used in this study
- Have a known allergy to adhesives that would prevent proper attachment of the Continuous Glucose Monitoring sensors
- Are pregnant and/or have been pregnant in the last year or are lactating and/or breastfeeding
- Are currently suffering from, or have ever suffered from eating disorders, any diagnosed gastrointestinal disease, gastrointestinal disorders including regular diarrhoea and constipation (excluding hiatus hernia unless symptomatic) or other inflammatory diseases like rheumatoid arthritis (RA), polymyalgia rheumatica or other connective tissues diseases
- Have undergone gastrointestinal surgery; this will be assessed on an individual basis
- Have been diagnosed with diabetes, anaemia as this may affect the study outcome
- Have been diagnosed with any long-term medical condition that may affect the study outcome (e.g. cardiovascular diseases, cancer)
- Regularly take over-the-counter medications for digestive/gastrointestinal conditions
- Use medications likely to interfere with energy metabolism, appetite regulation and hormonal balance, including long-term steroids, antibiotics. They may be able to participate if 4 weeks or more have passed from the end of a course such medication
- Regularly take laxatives (once a month or more) as this may affect blood glucose levels
- Take certain dietary supplements or herbal remedies and are unwilling to stop taking them (if required) for two weeks prior to and during the study period
- Are on, or plan to start, a diet programme that may affect the study outcome (e.g. 5:2 fasting diet) unless willing to abstain for 1 month prior to and during the study period
- Went through a weight change of ≥ 3kg in the preceding 2 months
- Have a recent history of substance abuse
- Regularly consume more than 14 units of alcohol a week
- Are unwilling to suspend smoking and vaping for the duration of the study.
- Are participating in another research project that involves dietary intervention or blood sampling.
- Are unwilling to provide GPs contact details
- Are related to or living with any member of the study team.
- Are unable to provide written informed consent
- Have not donated blood or taken part in another dietary intervention in the last 16 weeks and are unwilling to wait until 16 weeks have elapsed
- Those with abnormal blood pressure measurements
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: sbeIIa/b white bread
sbeIIa/b white bread with high resistant starch content
|
one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
|
Active Comparator: Control white bread
Reference white bread (wild-type)
|
one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in postprandial capillary glucose concentration
Time Frame: 3.5 hours
|
Glucose concentration in capillary blood measured by finger prick test after the consumption of sbeIIa/b white bread compared to control white bread. Measurements will be taken during intervention visit 1 and 2 at -15, -10, -5, 15, 30, 45, 60, 75, 90, 120, 150, 180, 210 min. |
3.5 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in postprandial glucose concentration in interstitial fluid
Time Frame: 4 hours
|
Glucose concentration in interstitial fluid measured by continuous glucose monitoring system after the consumption of sbeIIa/b white bread compared to control white bread. Measurements will be taken during intervention visit 1 and 2 between -30 to 210 min. |
4 hours
|
Ad libitum intake
Time Frame: 2 hours
|
Mean energy intake (kcal) at lunch after consumption of sbeIIa/b and control white bread. Measurements will be taken once during intervention visit 1 and 2. |
2 hours
|
Change in postprandial glucose concentration in interstitial fluid
Time Frame: 4 hours
|
Glucose concentration in interstitial fluid measured by continuous glucose monitoring system after the consumption of ad libitum lunch to explore any second meal effects caused by prior intake of either sbeIIa/b white bread and control white bread at breakfast. Measurements will be taken during intervention visit 1 and 2 between 225 to 465 min. |
4 hours
|
Satiety
Time Frame: 3 hours
|
Change of hunger feeling (appetite) will be examined using visual analog scale (0-10), 0 least and 10 greatest. Measurements will be taken during intervention visit 1 and 2, at 0, 32, 92, 182 min. |
3 hours
|
Sensory questionnaire
Time Frame: 30 minutes
|
Sensory perception of sbeIIa/b white bread and control white bread will be evaluated using a nine-point hedonic scale to determine any differences overall acceptability based on specific attributes. A Just-About-Right (JAR) scale with five anchor points will be used to measure the appropriateness of the level of specific attributes to evaluate aroma, appearance, taste and texture of breads. Measurements will be taken once during intervention visit 1 and 2. |
30 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marina Corrado, MSc, PhD student
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- QIB02/2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Glucose Response
-
University Malaysia SarawakCompleted
-
Aventure ABCompletedBlood Glucose ResponseSweden
-
University of LeedsSugar Nutrition, UKCompletedCognitive Performance | Blood Glucose Response | Self-controlUnited Kingdom
-
Clinical Nutrition Research Centre, SingaporeUniversity of GuelphCompleted
-
University of UdineWageningen University and ResearchActive, not recruitingGlycemic Index | Oral Processing | Glucose Response | Insulin ResponseItaly
-
NestléCompletedPostprandial Glucose ResponseSwitzerland
-
KU LeuvenRecruitingGastric Emptying | Energy Intake | Satiety | Appetite | Glucose Response | Insulin ResponseBelgium
-
Mondelēz International, Inc.Glycemic Index Laboratories, IncCompleted
-
Texas A&M UniversityNutraboltCompletedGlucose and Insulin Response
-
West German Center of Diabetes and HealthBionorica SECompletedPostprandial Glucose Response | Glycaemic Index | Continous Glucose MeasurementGermany
Clinical Trials on sbeIIa/b white bread
-
Organización Interprofesional Agroalimentaria de...Universidad de GranadaCompleted
-
Paulic Meunerie SAInstitut Polytechnique UniLaSalleCompleted
-
Nutrition Institute, SloveniaValens Int. d.o.o., SlovenijaCompleted
-
Newcastle-upon-Tyne Hospitals NHS TrustBiotechnology and Biological Sciences Research CouncilCompleted
-
University College DublinActive, not recruitingGlucose Intolerance | Healthy Subjects | Postprandial Hyperglycemia | Glycemic Control | Diabetes Mellitus RiskIreland
-
Ohio State UniversityUSDA Beltsville Human Nutrition Research CenterActive, not recruitingInflammation | PreDiabetes | Endotoxemia | DysbiosisUnited States
-
Nutrition Institute, SloveniaSlovenian Research Agency; Valens Int. d.o.o., Slovenija; Community Health Centre...CompletedGlycemic IndexSlovenia
-
Glycemic Index Laboratories, IncUniversity of Guelph; Guelph Research and Development Centre, Agriculture and...Completed
-
University of ReadingBiotechnology and Biological Sciences Research CouncilCompletedCardiovascular Risk FactorUnited Kingdom
-
National Pingtung University Science and TechnologyCompleted